共 50 条
- [41] Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 ExpressionCANCER RESEARCH COMMUNICATIONS, 2024, 4 (03): : 822 - 833Crump, Lyndsey S.Floyd, Jessica L.Kuo, Li-WeiPost, Miriam D.Bickerdike, MikeO'Neill, KathleenSompel, KaylaJordan, Kimberly R.Corr, Bradley R.Marjon, NicoleWoodruff, Elizabeth R.Richer, Jennifer K.Bitler, Benjamin G.
- [42] Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomasNEUROPATHOLOGY, 2019, 39 (06) : 413 - 424Jha, PreranaManjunath, NivedithaSingh, JyotsnaMani, KalaivaniGarg, AjayKaur, KavneetSharma, Mehar C.Raheja, AmolSuri, AshishSarkar, ChitraSuri, Vaishali
- [43] PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activationAMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (05): : 2363 - +Xue, ZhenZheng, ShuangLinghu, DongliLiu, BoningYang, YiChen, Mei-KuangHuang, HuaSong, JiamingLi, HongyueWang, JingHung, Mien-ChieZhong, DianshengSun, Linlin
- [44] PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic TumorsJOURNAL OF IMMUNOTHERAPY, 2015, 38 (01) : 1 - 11Soares, Kevin C.Rucki, Agnieszka A.Wu, Annie A.Olino, KellyXiao, QianChai, YiWamwea, AnthonyBigelow, ElaineLutz, EricLiu, LindaYao, ShengAnders, Robert A.Laheru, DanielWolfgang, Christopher L.Edil, Barish H.Schulick, Richard D.Jaffee, Elizabeth M.Zheng, Lei
- [45] PD-L1 inhibition with avelumab for metastatic Merkel cell carcinomaEXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 345 - 359Gaiser, Maria RitaBongiorno, MichelleBrownell, Isaac
- [46] BRAIN CELLS MODULATE ENCEPHALITOGENIC T-CELL RESPONSES VIA PD-1: PD-L1JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2013, 8 (02) : 418 - 419Hu, S.Schachtele, S. J.Mutnal, M. B.Sheng, W. S.Lokensgard, J. R.
- [47] Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaCLINICAL CANCER RESEARCH, 2020, 26 (09) : 2257 - 2267Spassova, IvelinaUgurel, SelmaTerheyden, PatrickSucker, AntjeHassel, Jessica C.Ritter, CathrinKubat, LindaHabermann, DanielFarahpour, FarnoushSaeedghalati, MohammadkarimPeiffer, LukasKumar, RajivSchrama, DavidHoffmann, DanielSchadendorf, DirkBecker, Juergen C.
- [48] An NK cell line (PD-L1 t-haNK) engineered to target PD-L1 efficiently kills tumor cells and myeloid derived suppressor cellsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Fabian, KellsyePadget, MichelleDonahue, ReneeSolocinski, KristenAllen, ClintLee, JohnSoon-Shiong, PatrickSchlom, JeffreyHodge, James
- [49] PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?BMC Cancer, 18Ramón Cantero-CidJosé Casas-MartinEnrique Hernández-JiménezCarolina Cubillos-ZapataAníbal Varela-SerranoJosé Avendaño-OrtizMarta CasarrubiosKarla Montalbán-HernándezIgnacio Villacañas-GilLaura Guerra-PastriánBegoña PeinadoCristóbal MarcanoLuis A AguirreEduardo López-Collazo
- [50] In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapyNANO TODAY, 2022, 44Yang, WeijingZhang, MengZhang, JinjieLiu, YanlongNing, JieYang, JingZhang, ZhenzhongHou, LinChen, Xiaoyuan